The European Medicines Agency (EMA) has granted "orphan designation" to BMS 204352, a molecule developed by the CNRS to treat Fragile X Syndrome, a rare genetic disease for which there exists no treatment. Protocol assistance will therefore be provided by the EMA to Dr Sylvain Briault at the Centre Hospitalier Régional in Orléans (west-central France) and his team at the Immunologie et Neurogénétique Expérimentales et Moléculaires laboratory - INEM (CNRS/University of Orléans) during the clinical development of the molecule.
↧